| abstract |
Pharmaceutical formulations for treating vaginal conditions in human patients include at least one active substance, an improved release dosage form that provides sustained release of an anti-infective agent upon intravaginal administration to the patient, wherein the formulation Is a plasma concentration versus time curve having an area under the curve (AUC) of about 600 ng / mL.hr or less (AUC) when containing a total dose of about 25 μg to about 500 mg of an anti-infective drug based on the active agent ( ng / mL vs. time). |